Error: Could not add to watchlist. X
+ Watchlist

Avanir Pharmaceuticals Inc

AVNR:US
Acquired
AVNR:US was acquired by OTSKZ:JP
USD
Volume
0
Before it's here, it's on the Bloomberg Terminal.
Learn More
Volume
0
Current P/E Ratio (TTM)
-
Earnings per Share (USD) (TTM)
-0.31
Market Cap (USD)
-
Shares Outstanding (m)
193.759
Price/Sales (TTM)
-
Dividend Indicated Gross Yield
-
Sector
Health Care
% Price Change
+0.74%
% Price Change
+0.85%

Related Videos

There are currently no related videos for this ticker. Please check back later.
There are currently no news stories for this ticker. Please check back later.
There are currently no press releases for this ticker. Please check back later.
Profile
Avanir Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases. The Company develops treatments for pseudobulbar affect, diabetic peripheral neuropathic pain, and other conditions. Avanir out-licensed its moniclonal antibodies, and produces an over-the-counter treatment for cold sores.
Address
101 Enterprise
Suite 300
Aliso Viejo, CA 92656
United States
Phone
1-949-389-6700
Show More